A
Anouk C. Vedder
Researcher at University of Amsterdam
Publications - 17
Citations - 2061
Anouk C. Vedder is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Fabry disease & Globotriaosylceramide. The author has an hindex of 14, co-authored 17 publications receiving 1902 citations.
Papers
More filters
Journal ArticleDOI
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
Johannes M. F. G. Aerts,Johanna E. M. Groener,Sijmen Kuiper,Wilma E. Donker-Koopman,Anneke Strijland,Roelof Ottenhoff,Cindy P. A. A. van Roomen,Mina Mirzaian,Frits A. Wijburg,Gabor E. Linthorst,Anouk C. Vedder,Saskia M. Rombach,Josanne Cox-Brinkman,Pentti Somerharju,Rolf G. Boot,Carla E. M. Hollak,Roscoe O. Brady,Ben J. H. M. Poorthuis +17 more
TL;DR: It is shown that globotriaosylsphingosine is an inhibitor of α-galactosidase A activity and the increased intima-media thickness in Fabry patients therefore may be related to the presence of this metabolite.
Journal ArticleDOI
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Dominique P. Germain,Stephen Waldek,Maryam Banikazemi,Maryam Banikazemi,David A. Bushinsky,Joel Charrow,Robert J. Desnick,Philip J. Lee,Thomas W. Loew,Anouk C. Vedder,Rekha Abichandani,William R. Wilcox,Nathalie Guffon +12 more
TL;DR: Long-term agalsidase beta therapy stabilizes renal function in patients without renal involvement at baseline, maintains reduction of plasma GL-3, and sustainsGL-3 clearance in capillary endothelial cells and multiple renal cell types.
Journal ArticleDOI
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
Anouk C. Vedder,Gabor E. Linthorst,Gunnar Houge,Johannna E.M. Groener,Els E. Ormel,Berto J. Bouma,Johannes M. F. G. Aerts,Asle Hirth,Carla E. M. Hollak +8 more
TL;DR: No difference in reduction of left ventricular mass or other disease parameters after 12 and 24 months of treatment with either agalsidase alfa or beta at a dose of 0.2 mg/kg biweekly is revealed.
Journal ArticleDOI
The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels
Anouk C. Vedder,Gabor E. Linthorst,M. J. van Breemen,J. E. M. Groener,F. J. Bemelman,A. Strijland,Marcel M.A.M. Mannens,Johannes M. F. G. Aerts,C. E. M. Hollak +8 more
TL;DR: Analysis of the characteristics of the Dutch Fabry cohort has revealed that a limited relationship between various disease manifestations exists and that individual symptoms do not correlate with elevated urinary or plasma Gb3 levels, limiting their value as surrogate disease markers.